Gary Landreth, Ph.D.

AD projects in Dr. Landreth’s laboratory are directed at understanding how the beta-amyloid peptides are normally cleared from the brain and the roles of inflammation in AD pathogenesis. The lab is also engaged in identification and validation of new therapeutic agents for the treatment of AD.  Dr. Landreth received his B.A. from the University of Kansas, and his Ph.D. from the University of Michigan.

Funded Research

These projects were made possible from Cure Alzheimer's Fund support.

Selected Publications

These published papers resulted from Cure Alzheimer’s Fund support.

Claes, C., England, W. E., Danhash, E. P., Kiani Shabestari, S., Jairaman, A., Chadarevian, J. P., Hasselmann, J., Tsai, A. P., Coburn, M. A., Sanchez, J., Lim, T. E., Hidalgo, J. L. S., Tu, C., Cahalan, M. D., Lamb, B. T., Landreth, G. E., Spitale, R. C., Blurton-Jones, M., & Davtyan, H. The P522R protective variant of PLCG2 promotes the expression of antigen presentation genes by human microglia in an Alzheimer’s disease mouse model, Alzheimer's & Dementia, February 9, 2022, Read More

Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., Brunden, K. R., Wilson, D. A., & Landreth, G. E. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models, Science, March 23, 2012, Read More